Fmr LLC Has $47.15 Million Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Fmr LLC decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 6.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 3,209,436 shares of the company’s stock after selling 228,450 shares during the period. Fmr LLC’s holdings in Elanco Animal Health were worth $47,147,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ELAN. Commerce Bank increased its position in shares of Elanco Animal Health by 2.2% during the third quarter. Commerce Bank now owns 35,114 shares of the company’s stock worth $516,000 after acquiring an additional 741 shares in the last quarter. 180 Wealth Advisors LLC increased its holdings in Elanco Animal Health by 3.6% during the 2nd quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock worth $352,000 after purchasing an additional 893 shares in the last quarter. HBK Sorce Advisory LLC raised its stake in shares of Elanco Animal Health by 9.4% in the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock worth $186,000 after purchasing an additional 1,107 shares during the last quarter. Atomi Financial Group Inc. raised its stake in shares of Elanco Animal Health by 11.1% in the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock worth $177,000 after purchasing an additional 1,221 shares during the last quarter. Finally, Keene & Associates Inc. lifted its holdings in shares of Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock valued at $337,000 after purchasing an additional 1,240 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $12.50 on Friday. The company has a market capitalization of $6.18 billion, a PE ratio of 31.25, a price-to-earnings-growth ratio of 1.98 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a 52-week low of $11.40 and a 52-week high of $18.80. The company has a 50-day simple moving average of $13.43 and a 200 day simple moving average of $14.47.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the firm posted $0.18 EPS. Elanco Animal Health’s revenue was down 3.6% on a year-over-year basis. On average, research analysts predict that Elanco Animal Health Incorporated will post 0.92 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on ELAN. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Barclays lifted their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $16.57.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.